Phase 1B, Open-Label, Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Investigational Ebola Vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in Healthy Adults in Kampala Uganda.

Trial Profile

Phase 1B, Open-Label, Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Investigational Ebola Vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in Healthy Adults in Kampala Uganda.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs GSK 3390107A (Primary) ; VRC-EBOADC069-00-VP (Primary)
  • Indications Ebola virus infections; Fever
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 18 Dec 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
    • 22 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top